Alvoetin

Alvoetin

epoetin alfa

Manufacturer:

MR Pharma

Distributor:

Maxxcare

Marketer:

Mega Lifesciences
Concise Prescribing Info
Contents
Epoetin α
Indications/Uses
Symptomatic anaemia associated w/ chronic renal failure in adult & paed patients on haemodialysis & adult patients on peritoneal dialysis. Severe anaemia in adult patients w/ renal insufficiency not yet undergoing dialysis. Anaemia & reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, & at risk of transfusion. Increase yield of autologous blood in predonation programme in patients w/ moderate anaemia. Reduction of exposure to allogeneic blood transfusions prior to major elective orthopaedic surgery. Anaemia related w/ zidovudine therapy in HIV-infected patients.
Dosage/Direction for Use
IV/SC Symptomatic anaemia in chronic renal failure patients Adult on haemodialysis Correction phase: 50 IU/kg 3 times/wk. Increase or reduce dose if necessary in steps of 25 IU/kg 3 times/wk in intervals of at least 4 wk. Maintenance phase: Total wkly dose: 75-300 IU/kg. Paed on haemodialysis Correction phase: 50 IU/kg IV 3 times/wk. Adjust dose if necessary in steps of 25 IU/kg 3 times/wk at intervals of at least 4 wk until desired goal is achieved. Maintenance phase: >30 kg 30-100 IU/kg 3 times/wk, 10-30 kg 60-150 IU/kg 3 times/wk, <10 kg 75-150 IU/kg 3 times/wk. Adult w/ renal insufficiency not on dialysis Correction phase: Initially 50 IU/kg 3 times/wk followed by dose increase w/ 25 IU/kg increments (3 times/wk) in steps of at least 4 wk if necessary until desired goal is achieved. Maintenance phase: 17-33 IU/kg 3 times/wk. Max: 200 IU/kg 3 times/wk. Adult on peritoneal dialysis Correction phase: Initially 50 IU/kg 2 times/wk. Maintenance phase: 25-50 IU/kg 2 times/wk into 2 equal inj. Chemotherapy induced anaemia Initially 150 IU/kg SC 3 times/wk until 1 mth after end of chemotherapy. Alternatively, 450 IU/kg SC once wkly. Adult surgery patient in autologous predonation programme Mildly anaemic patient requiring predeposit of ≥4 units of blood: 600 IU/kg IV 2 times wkly for 3 wk prior to surgery. Adult patient scheduled for major elective orthopaedic surgery 600 IU/kg SC wkly for 3 wk (days -21, -14, -7) prior to & on day of surgery. Give 300 IU/kg daily for 10 consecutive days prior to, on day of surgery & for 4 days immediately thereafter when lead time before surgery is needed to be shortened to <3 wk. Zidovudine-treated HIV-infected adult patient Initially 100 IU/kg IV/SC inj 3 times/wk for 8 wk. Increase dose by 50-100 IU/kg 3 times/wk if response is not satisfactory.
Contraindications
Hypersensitivity. Known sensitivity to human albumin. Patients who develop pure red cell aplasia (PRCA) following treatment. Uncontrolled HTN. Patients w/ severe coronary, peripheral arterial, carotid or cerebral vascular disease (including recent MI or CVA) who are scheduled for major elective orthopaedic surgery & not participating in autologous blood predonation programme. Surgery patients who cannot receive adequate antithrombotic prophylaxis.
Special Precautions
Not for use in management of anaemia associated w/ hepatitis C. Monitor BP, Hb levels (twice a wk in chronic renal failure patients & once a wk in zidovudine-treated HIV-infected & cancer patients), platelet counts (1st 8 wks of therapy). Regularly monitor serum electrolytes & for loss of efficacy in chronic renal failure patients. Treat other causes of anaemia prior to initiating therapy w/ epoetin alfa. HTN, epilepsy, chronic liver failure, porphyria, known history of seizure disorder or underlying hematologic disease. Patients scheduled for major elective orthopaedic surgery may be at risk of thrombotic/vascular events; not to be used in patients w/ baseline Hb >13 g/dL. Cancer patients w/ increased risk of thrombotic vascular events. Dialysis patients are advised not to engage in potentially hazardous activities (eg, driving or operating heavy machinery). Pregnancy & lactation.
Adverse Reactions
Nausea; headache; arthralgia. HTN; vomiting; flu-like illness. Cancer patients: Pyrexia. DVT; pulmonary embolism; diarrhoea. Chronic renal failure patients: Seizures; shunt thromboses including dialysis equipment.
Drug Interactions
ATC Classification
B03XA01 - erythropoietin ; Belongs to the class of other antianemic preparations. Used in the treatment of anemia.
Presentation/Packing
Form
Alvoetin soln for inj 4000 iu/mL
Packing/Price
1 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in